Parameter
| Biomarker | PD-L1 | Full name | Programmed death-ligand 1 | Molecular Type | Protein |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Diagnostic and therapeutic targets | ||
| Disease | Non-Hodgkin Lymphoma (NHL) | Disease Subtypes | / | ||
| Organ | Lymphoid tissue | Test Sample / Technology Platform | Blood, tissues (flow cytometry, immunohistochemistry) | ||
| Pathobiological Mechanisms | High expression of lymphocyte apoptosis-promoting mediates immune evasion | ||||
| Clinical Availability Status | Clinical validation phase: Multi-study support value, platform consistency for testing requires optimization, partial subtype applications. | ||||
| Notes and Dynamics | Developing subtype detection guidelines and exploring their combined predictive value with CD8+ T cells. | ||||